Freestyle Bioprosthesis
Medtronic, Inc. · Decision date Nov 10, 2025
What did the FDA approve?
FDA records P970031/S076 as a supplement to PMA P970031, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 10, 2025.
FDA approval order statement
Approval for implementation of updates to the product labels and IFUs, and the implementation of a new temperature indicator on the secondary package shelf cartons for the Mosaic, Hancock II, Avalus, and Freestyle bioprostheses
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 10, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P970031/S076
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LWR
- Decision code
- APPR
- Decision date
- Nov 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: heart-valve, non-allograft tissue.
- Applicant
- Medtronic, Inc.
- Product code
- LWR
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P970031/S076 received
Application receipt date recorded by FDA.
P970031/S077 · Related supplement
Freestyle Bioprosthesis, Models 995, 995CS, 995MS
P970031/S076 · FDA decision
Real-Time Process
P970031/S078 · Related supplement
Freestyle Bioprosthesis
Timeline entries are records held by MedtechLedger for P970031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 23, 2025 | FDA | |
Freestyle BioprosthesisP970031/S078 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
Explore the linked device profile
Other records with product code LWR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EDWARDS INTUITY Elite Valve System (8300AB)P150036/S081 | Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Aug 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 1851 E. Deere Ave., Santa Ana, CA, 92705
Sources and methodology
- Original FDA record: P970031/S076
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

